Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Elliquis

- PMLiVE

Syndax teams with Merck/Pfizer on immuno-oncology combo

Oral cancer drug entinostat to test with avelumab

- PMLiVE

Keytruda bounces back in rivalry with Opdivo

First drug in its class to secure FDA approval as a first-line therapy for malignant melanoma

- PMLiVE

NHS patients set to be denied Opdivo and Kadcyla

NICE rejects BMS and Roche cancer treatments

- PMLiVE

Quintiles wins New Models of Care award at PMEA

Rewarded for its rheumatology project for Pfizer

- PMLiVE

Xalkori set for rapid review in new lung cancer indication

Pfizer could produce first FDA-approved biomarker-driven therapy for ROS1-positive NSCLC

- PMLiVE

Pfizer signs $1bn cancer antibody deal with BioAtla

Aims to overcome one of the limitations of antibody-drug conjugate drugs

- PMLiVE

UK site a casualty as Pfizer reduces pain R&D

Will shut down Granta Park facility in Cambridge with loss of 120 jobs

- PMLiVE

Pfizer’s Xalkori approved for wider use in Europe

Labelupdate gives the lung cancer therapy a new first-line indication

- PMLiVE

Pfizer signs high-level deal with GPCR specialist Heptares

Wide-rangingdeal will involve up to 10 drug targets

Michael Parini moves from Pfizer to Vertex

Will be the USbiotech's chief legal officer

Bristol-Myers Squibb (BMS) building

Opdivo cleared for kidney cancer and first-line melanoma

First drug to show survival benefit in kidney cancer since 2007

- PMLiVE

Pfizer and Allergan merger faces opposition over tax

Companiesagree deal to boost Pfizer's standing as world's largest pharma company

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links